US 12,441,782 B2
Anti-HIV antibody 10-1074 variants
Michel Nussenzweig, New York, NY (US); Randal R. Ketchem, Snohomish, WA (US); Christine C. Siska, Seattle, WA (US); Alison J. Gillespie, Seattle, WA (US); Rutilio H. Clark, Bainbridge Island, WA (US); and Bruce A Kerwin, Bainbridge Island, WA (US)
Assigned to The Rockefeller University, New York, NY (US)
Appl. No. 17/275,310
Filed by The Rockefeller University, New York, NY (US)
PCT Filed Sep. 12, 2019, PCT No. PCT/US2019/050823
§ 371(c)(1), (2) Date Mar. 11, 2021,
PCT Pub. No. WO2020/056145, PCT Pub. Date Mar. 19, 2020.
Claims priority of provisional application 62/731,356, filed on Sep. 14, 2018.
Prior Publication US 2022/0119504 A1, Apr. 21, 2022
Int. Cl. C07K 16/10 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 31/18 (2006.01)
CPC C07K 16/1045 (2013.01) [A61K 45/06 (2013.01); A61P 31/18 (2018.01); A61K 2039/507 (2013.01)] 16 Claims
 
1. An isolated anti-HIV antibody, or antigen-binding portion thereof, comprising a light chain variable region having a light chain amino acid sequence that is at least 95% identical to SEQ ID NO: 24, wherein the light chain complementarity determining regions (CDRL1, CDRL2, and CDRL3) of the antibody or antigen-binding portion thereof comprise the CDRL1 of SEQ ID NO: 233 (GRQALGSRAVQ), the CDRL2 of SEQ ID NO: 234 (NNQDRPS), and the CDRL3 of SEQ ID NO: 235 (HMWDSRSGFSWS), and
a heavy chain variable region having a heavy chain amino acid sequence that is at least 95% identical to SEQ ID NO: 71, wherein the heavy chain complementarity determining regions (CDRH1, CDRH2, and CDRH3) of the antibody or antigen-binding portion thereof comprises the CDRH1 of SEQ ID NO: 236 (NNYYWT), the CDRH2 of SEQ ID NO: 237 (YISDRESATYNPSLNS) and the CDRH3 of SEQ ID NO: 238 (ARRGQRIYGVVSFGEFFYYYSMDV),
wherein (i) the light chain amino acid sequence comprises a residue at position 21 with respect to SEQ ID NO: 24 that is not Tyr or
(ii) the heavy chain amino acid sequence comprises a residue at position 87 with respect to SEQ ID NO: 71 that is not Val, a residue at position 97 with respect to SEQ ID NO: 71 that is not Leu, and a residue at position 116 with respect to SEQ ID NO: 71 that is not Thr, and wherein the anti-HIV antibody, or antigen-binding portion thereof retains its ability to bind to HIV.